Novartis: ACZ885 reduces cardiovascular risk.
(CercleFinance.com) - Novartis said on Monday that a phase III study demonstrated that targeting inflammation with its human monoclonal antibody ACZ885 has enabled a reduction in cardiovascular risk.
The study showed a 15% reduction of major adverse cardiovascular events in people with heart attack precedent and inflammatory atherosclerosis who were treated with ACZ885, in addition to standard of care including lipid-lowering therapy, the drugmaker said.
Novartis said that a sub-group responder analysis showed that the 50% of patients who achieved a high-sensitivity C-reactive protein (hsCRP) value of less than the median at three months after the first injection even experienced a 27% relative risk reduction on the primary major adverse cardiovascular events (MACE) end-point.
Novartis also said that analysis published in The Lancet showed ACZ885 reduced lung cancer mortality by 77% in the study, with further studies planned.
ACZ885 inhibits a key cytokine in the inflammatory pathway known to drive the continued progression of inflammatory atherosclerosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The study showed a 15% reduction of major adverse cardiovascular events in people with heart attack precedent and inflammatory atherosclerosis who were treated with ACZ885, in addition to standard of care including lipid-lowering therapy, the drugmaker said.
Novartis said that a sub-group responder analysis showed that the 50% of patients who achieved a high-sensitivity C-reactive protein (hsCRP) value of less than the median at three months after the first injection even experienced a 27% relative risk reduction on the primary major adverse cardiovascular events (MACE) end-point.
Novartis also said that analysis published in The Lancet showed ACZ885 reduced lung cancer mortality by 77% in the study, with further studies planned.
ACZ885 inhibits a key cytokine in the inflammatory pathway known to drive the continued progression of inflammatory atherosclerosis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.